Wegovy Lowered Users’ Heart Risks in New Trial
TUESDAY, Aug. 8, 2023 (HealthDay News) — A large clinical trial weighing the medical merits of the obesity drug Wegovy (semaglutide) has unearthed a significant positive side effect. Taking the medication cut the risk for serious heart problems by 20…
Learn MoreGeneric, Brand-Name Medication Similarly Effective for COPD
MONDAY, Aug. 7, 2023 (HealthDay News) — For patients with chronic obstructive pulmonary disease (COPD), generic and brand-name fluticasone-salmeterol are similarly effective and safe, according to a study published online Aug. 8 in the Annals of Inte…
Learn MoreUnderstanding the Different Types of Breast Cancer Treatment
The battle against breast cancer has produced significant triumphs in recent years, with new and tailored treatments now offering patients more options for fighting their disease.The statistics confirm that more and better treatments are translating i…
Learn MoreStudy Cannot Exclude Benefit of Progesterone for Vasomotor Symptoms
FRIDAY, Aug. 4, 2023 (HealthDay News) — For perimenopausal women with hot flushes with or without night sweats, a minimal clinically important vasomotor symptom (VMS) benefit cannot be ruled out for oral micronized progesterone, according to a study …
Learn MoreHigh-Dose VX-548 Reduces Acute Pain Over 48 Hours
FRIDAY, Aug. 4, 2023 (HealthDay News) — High-dose VX-548, an oral, highly selective inhibitor of the Nav1.8 voltage-gated sodium channel, reduces acute pain over 48 hours after abdominoplasty and bunionectomy, according to a study published in the Au…
Learn MoreGlycemic Control Superior With Semaglutide 25 and 50 mg in Type 2 Diabetes
FRIDAY, Aug. 4, 2023 (HealthDay News) — Once-daily semaglutide 25 mg or 50 mg is superior to 14 mg for glycemic control among adults with type 2 diabetes, according to a study published online June 25 in The Lancet.Vanita R. Aroda, M.D., from Brigham…
Learn MoreFDA Approves Second OTC Naloxone Spray for Suspected Opioid Overdose
THURSDAY, Aug. 3, 2023 (HealthDay News) — The U.S. Food and Drug Administration has approved RiVive, an over-the-counter (OTC) naloxone hydrochloride nasal spray for emergency treatment of known or suspected opioid overdose.”We know naloxone is a pow…
Learn MoreLawsuit Against Makers of Ozempic, Mounjaro Claim Meds Caused ‘Stomach Paralysis’
THURSDAY, Aug. 3, 2023 (HealthDay News) — A Louisiana woman is suing the makers of two type 2 diabetes drugs used off-label for obesity, saying they failed to adequately warn about the risk for severe stomach problems.The lawsuit seeks “very signific…
Learn MoreHigher Belly Fat Percentage Tied to Worse Outcomes for IBD Patients
WEDNESDAY, Aug. 2, 2023 (HealthDay News) — For patients with inflammatory bowel disease (IBD), higher intra-abdominal visceral adipose tissue (IA-VAT) as a percentage of total body mass is associated with worse outcomes and may increase resistance to…
Learn MoreAmid Shortages, Federal Agencies Ask Drugmakers to Boost Output of ADHD Meds
WEDNESDAY, Aug. 2, 2023 (HealthDay News) — While demand for prescription stimulants is surging, a shortage of the drugs persists, so federal officials have stepped in and asked drug companies to ramp up production of the medications.Officials from bo…
Learn More